{
    "organizations": [],
    "uuid": "f1f8ba1a434dd3abc5ba1d75b2b73f9ac9311120",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-opiant-pharma-says-teva-filed-anda/brief-opiant-pharma-says-teva-filed-anda-with-fda-for-marketing-approval-of-generic-version-of-narcan-2-mg-spray-idUSFWN1QN0QW",
    "ord_in_thread": 0,
    "title": "BRIEF-Opiant Pharma Says Teva Filed ANDA With FDA For Marketing Approval Of Generic Version Of Narcan 2 Mg/Spray",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Opiant Pharmaceuticals Inc:\n* OPIANT PHARMACEUTICALS SAYS ON FEB 27, CO AND ADAPT PHARMA OPERATIONS LIMITED RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA INC - SEC FILING\n* OPIANT PHARMACEUTICALS - TEVA FILED ANDA WITH FDA FOR MARKETING APPROVAL OF GENERIC VERSION OF NARCAN 2 MG/SPRAY NASAL SPRAY BEFORE EXPIRY OF CERTAIN U.S. PATENTS Source text: ( bit.ly/2I5daXC ) Further company coverage:\n ",
    "published": "2018-03-06T05:27:00.000+02:00",
    "crawled": "2018-03-06T22:26:48.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "opiant",
        "pharmaceutical",
        "inc",
        "opiant",
        "pharmaceutical",
        "say",
        "feb",
        "co",
        "adapt",
        "pharma",
        "operation",
        "limited",
        "received",
        "notice",
        "teva",
        "pharmaceutical",
        "usa",
        "inc",
        "sec",
        "filing",
        "opiant",
        "pharmaceutical",
        "teva",
        "filed",
        "anda",
        "fda",
        "marketing",
        "approval",
        "generic",
        "version",
        "narcan",
        "nasal",
        "spray",
        "expiry",
        "certain",
        "patent",
        "source",
        "text",
        "company",
        "coverage"
    ]
}